Skip to main content

Advertisement

SpringerLink
Log in

Chasing Rainbows? the Possibility of “Cure” in Patients with Colorectal Peritoneal Metastases Undergoing Cytoreductive Surgery and HIPEC—a Retrospective Study by INDEPSO

  • Original Article
  • Published:
Indian Journal of Surgical Oncology Aims and scope Submit manuscript

Abstract

Cytoreductive surgery (CRS) and HIPEC results in a median disease-free survival (DFS) of 12–15 months, overall survival (OS) of 23–63 months, and cure in around 15% of patients with colorectal peritoneal metastases (CPM). The wide variation in OS may largely be attributed to different criteria for patient selection employed by different investigators. To evaluate outcomes of CRS and HIPEC for CPM in patients enrolled in the Indian HIPEC registry. A retrospective analysis of patients enrolled in the registry since its inception in March 2016 was performed. The impact of various prognostic factors on DFS and OS was evaluated. From Jan 2013 to Dec 2017, 68 patients underwent CRS with HIPEC at six Indian centers. The median PCI was nine [range 3–35]. Twenty-two (32.3%) had mucinous tumors. A CC-0 resection was performed in 53 (77.9%) and CC-1 in 14 (20.5%). The median DFS was 12 months [95% CI 11.037–12.963 months] and the median OS 25 months [95% CI 18.718–31.282]. The DFS was inferior in patients with right upper quadrant involvement (p = 0.02) and 90-day major morbidity (p = 0.002) and OS inferior in those with 90-day major morbidity (p < 0.001) and mucinous tumors with a PCI > 20. The DFS compares well with results obtained by pioneering teams but we have no “cured” patients. Better patient selection and utilization of systemic therapies could in the future improve the OS. There is a compelling need to identify subgroups of CPM that benefit from the addition of HIPEC to CRS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Goéré D, Malka D, Tzanis D, Gava V, Boige V, Eveno C, Maggiori L, Dumont F, Ducreux M, Elias D (2013) Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg 257:1065–1071

    Article  PubMed  Google Scholar 

  2. Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M, et al (2018) A UNICANCER phase III trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for col- orectal peritoneal carcinomatosis (PC): PRODIGE 7 [Internet]. J Clin Oncol. [cited 2018 Jul 17];36:LBA3503-LBA3503 Available from. http://ascopubs.org/doi/10.1200/JCO.2018.36.18_suppl.LBA3503

  3. Baratti D, Kusamura S, Pietrantonio F, Guaglio M, Niger M, Deraco M (2016) Progress in treatments for colorectal cancer peritoneal metastases during the years 2010–2015. A systematic review. Crit Rev Oncol Hematol 100:209–222

    Article  PubMed  Google Scholar 

  4. Bhatt A, Mehta S, Quenet F. Multimodality treatment for colorectal peritoneal metastases. In book: Management of peritoneal metastases- cytoreductive Surgery, HIPEC and beyond https://doi.org/10.1007/978-981-10-7053-212

  5. Glehen O, Kwiatkofski F, Sugarbaker PH, Elias D et al (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22:3284–3292

    Article  CAS  Google Scholar 

  6. Sluiter NR, Rovers KP, Salhi Y, Vlek SL, Coupé VMH, Verheul HMW, Kazemier G, de Hingh IHJT, Tuynman JB (2018) Metachronous peritoneal metastases after adjuvant chemotherapy are associated with poor outcome after cytoreduction and HIPEC. Ann Surg Oncol 25(8):2347–2356. https://doi.org/10.1245/s10434-018-6539-x

    Article  PubMed  PubMed Central  Google Scholar 

  7. Péron J, Mercier F, Tuech JJ, Younan R, Sideris L, Gelli M, Dumont F, Le Roy B, Sgarbura O, Lo Dico R, Bibeau F, Glehen O, Passot G, on behalf BIG-RENAPE working groups (2018) The location of the primary colon cancer has no impact on outcomes in patients undergoing cytoreductive surgery for peritoneal metastasis. Surgery:S0039-6060(18)30483-5. https://doi.org/10.1016/j.surg.2018.07.027

  8. Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S et al (2017) Pri- mary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Ann Oncol 28:1862–1868

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Ubink I, van Eden WJ, Snaebjornsson P, Kok NFM, van Kuik J, van Grevenstein WMU, Laclé MM, Sanders J, Fijneman RJA, Elias SG, Borel Rinkes IHM, Aalbers AGJ, Kranenburg O (2018 Jan) Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases. Br J Surg 105(2):e204–e211. https://doi.org/10.1002/bjs.10788

    Article  CAS  PubMed  Google Scholar 

  10. BFact sheets by population-CRC India ASRs. [Online]. Available: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx

  11. Goéré D, Souadka A, Faron M, Cloutier AS, Viana B, Honoré C, Dumont F, Elias D (2015) Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol 22:2958–2964

    Article  PubMed  Google Scholar 

  12. Elias D, Bonnay M, Puizillou JM, Antoun S, Dermirdjian S, El Otomany A et al (2002) Heated intra- operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmaco- kinetics and tissue distribution. Ann Surg Oncol 13:267–272

    Article  CAS  Google Scholar 

  13. Van der Speeten K, Stuart OA, Chang D et al (2011) Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol 68:147. https://doi.org/10.1007/s00280-010-1460-4

    Article  CAS  PubMed  Google Scholar 

  14. Witkamp AJ, van Coevorden F, Kaag MM, van Slooten GW, Beijnen JB, Boot H et al (1998) Dose finding study of hyperthermic intraperitoneal chemotherapy with mitomycin C in patients with carcinosis of colorectal origin. Eur J Surg Oncol 24:214

    Google Scholar 

  15. Pande R, Sunga A, Levea C, Wilding GE, Bshara W, Reid M, Fakih MG (2008) Significance of signet-ring cells in patients with colorectal cancer. Dis Colon Rectum 51:50–55

    Article  PubMed  Google Scholar 

  16. United States Department of Public Health and Human Services, NIH, NCI: Common Toxicity Criteria for Adverse Events (CTCAE). National Cancer Institute, June 2010. http://evs.nci.nih.gov/ftp1/CTCAE_Vers._4.03_2010-06-14;_QuickReference_5x7.pdf

  17. Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ III (2010) Cytoreductive surgery and hyperthermic intraperitoneal chemo- perfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer 116:3756–3762. https://doi.org/10.1002/cncr.25116

  18. Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dubè P, Glehen O (2010) Peritoneal colorec- tal carcinomatosis treated with surgery and periop- erative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28:63–68

    Article  Google Scholar 

  19. Saxena A, Yan TD, Morris DL (2010) A critical evaluation of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. World J Surg 34:70–78

    Article  PubMed  Google Scholar 

  20. Glockzin G, Zeman F, Croner RS, Königsrainer A, Pelz J, Ströhlein MA, Rau B, Arnold D, Koller M, Schlitt HJ, Piso P (2018) Perioperative systemic chemotherapy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy in patients with colorectal peritoneal metastasis: results of the prospective multicenter phase 2 COMBATAC Trial. Clin Colorectal Cancer

  21. Rovers KP, Simkens GA, Punt CJ, van Dieren S, Tanis PJ, de Hingh IH (2017) Perioperative systemic therapy for resectable colorectal peritoneal metastases: sufficient evidence for its widespread use? A critical systematic review. Crit Rev Oncol Hematol 114:53–62. https://doi.org/10.1016/j.critrevonc.2017.03.028

    Article  PubMed  Google Scholar 

  22. Golse N, Bakrin N, Passot G, Mohamed F, Vaudoyer D, Gilly FN, Glehen O, Cotte E (2012) Iterative procedures combining cytoreductive surgery with hyperther- mic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results. J Surg Oncol 106(2):197–203

    Article  PubMed  Google Scholar 

  23. Passot G, You B, Boschetti G, Fontaine J, Isaac S, Decullier E, Maurice C, Vaudoyer D, Gilly FN, Cotte E, Glehen O (2014) Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. Ann Surg Oncol 21:2608–2614

    Article  PubMed  Google Scholar 

  24. Sugarbaker PH (2016) Preoperative assessment of cancer patients with peritoneal metastases for complete cytoreduction. Indian J Surg Oncol 7(3):295–302

    Article  PubMed  PubMed Central  Google Scholar 

  25. Jacobson R, Sherman SK, Dadaleh F, Turaga KK (2018 Aug) Peritoneal metastases in colorectal cancer. Ann Surg Oncol 25(8):2145–2151

    Article  PubMed  Google Scholar 

  26. Roth L, Schneider M, Eden J, Pache B, Laminger F, Lopez-Lopez V, Steffen T et al (2018) Mutation of RAS/RAF-proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastases of colorectal origin. Pleura Peritoneum 1(Special Suppl):sA6–sA463

    Google Scholar 

  27. Pelz JOW, Stojadinovic A, Nissan A, Hohenberger W, Esquivel J (2009) Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol 99:9–15. https://doi.org/10.1002/jso.21169

    Article  Google Scholar 

  28. Huang Y, Alzahrani NA, Liauw W, Arrowaili A, Morris DL (2018) Survival difference between mucinous vs. non-mucinous colorectal cancer following cytoreductive surgery and intraperitoneal chemotherapy. Int J Hyperth 21:1–7

    Google Scholar 

  29. Brandl A, Weiss S, von Winterfeld M, Krannich A, Feist M, Pratschke J, Raue W, Rau B (2018) Predictive value of peritoneal cancer index for survival in patients with mucinous peritoneal malignancies treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a single centre experience. Int J Hyperthermia 34(5):512–517

    Article  PubMed  Google Scholar 

  30. Cashin PH, Mahteme H, Spång N, Syk I, Frödin JE, Torkzad M, Glimelius B, Graf W (2016) Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer 53:155–162. https://doi.org/10.1016/j.ejca.2015.09.017

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Zydus Hospital, Zydus Hospital Road, SG Highway, Thaltej, Ahmedabad, 380054, India

    Aditi Bhatt & Mahesh D. Patel

  2. Department of Surgical Oncology, Saifee Hospital, Mumbai, India

    Praveen Kammar & Sanket Mehta

  3. Department of Surgical Oncology, MVR Cancer Centre and Research Institute, Calicut, India

    Dileep Damodaran

  4. Department of Surgical Oncology, Manipal Hospital, Bangalore, India

    Shabber Zaveri

  5. Department of Surgical Oncology, Jehangir Hospital, Pune, India

    Snita Sinukumar

  6. Department of Surgical Oncology, All India Institute of Medical Sciences (AIIMS), New Delhi, India

    Mukurdipi Ray

  7. Department of Surgical Oncology, Cancer Institute, WIA, Chennai, India

    Ramakrishnan Seshadri

Authors
  1. Aditi Bhatt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Praveen Kammar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sanket Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dileep Damodaran
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shabber Zaveri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mahesh D. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Snita Sinukumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mukurdipi Ray
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ramakrishnan Seshadri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aditi Bhatt.

Ethics declarations

Conflicts of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bhatt, A., Kammar, P., Mehta, S. et al. Chasing Rainbows? the Possibility of “Cure” in Patients with Colorectal Peritoneal Metastases Undergoing Cytoreductive Surgery and HIPEC—a Retrospective Study by INDEPSO. Indian J Surg Oncol 10 (Suppl 1), 49–56 (2019). https://doi.org/10.1007/s13193-019-00879-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13193-019-00879-9

Keywords

Search

Navigation